2027-2029 Strategy:

Arcadis’ Reset: Focused Growth, Sustainable Value

  • Arcadis’ Reset: Focused Growth, Sustainable Value strategy is based on three value creation principles: Focus on Strengths, Simplify around Clients and Drive Performance Culture; all enabled by AI and digital innovation.
  • Divestment of the majority of the architecture business and China operations to accelerate value creation, expected to increase the operating EBITDA margin by ~100 basis points1).
  • Reduction of ~1,000 FTEs as part of overhead rightsizing targeted in 2027, with continued hiring in growth areas.
  • 2027–2029 financial targets:
    • Mid-single-digit organic net revenue growth;
    • Mid- to high-teens operating EBITDA margin;
    • Dividend payout ratio of 30–40% of net income from operations;
    • Net debt / operating EBITDA of 1.5–2.5x.
  • 2026 Financial guidance reaffirmed: low-single-digit organic net revenue growth, operating EBITA margin of 11.7–12.0%, equivalent to an operating EBITDA margin of 14.3–14.6%.
  • Non-financial targets set for 2027-2029 include: client satisfaction, Employee Net Promotor Score, safety improvement, and quantified material impact on sustainability through the Future IMPACT+ framework by 2035.

Amsterdam, 29 September 2026: Arcadis (EURONEXT: ARCAD), the leading global provider of data-driven sustainable design, engineering and consultancy solutions for natural and built assets, is hosting its Capital Markets Day in Amsterdam today to present its 2027–2029 strategy.

Heather Polinsky, Chief Executive Officer, said: “Arcadis’ Reset: Focused Growth, Sustainable Value sharpens our focus on the markets where demand is strongest, and our competitive differentiation is clear. Our people and our culture are what makes this possible, and our work addressing the world’s most complex infrastructure and environmental challenges is what makes it matter. We will invest in our Core and Accelerate industries, apply rigorous performance discipline to Optimize businesses, simplify the organization around clients and strengthen accountability. Combined with our leading market positions, specialist expertise and trusted client relationships, these actions are designed to translate our strategic strengths into stronger growth, higher margins and cash generation. We are building a more focused, higher-performing Arcadis that delivers sustainable value for shareholders, our people and our clients.”

Simon Crowe, Chief Financial Officer, said: “The financial rationale is compelling: a more focused portfolio, a structurally lower cost base and disciplined capital allocation will support higher margins, stronger cash generation and sustainable shareholder returns. The announced divestments are expected to increase the operating EBITDA margin by ~100 basis points1). Beyond this, we will improve win rates, drive billability and apply more targeted sales incentives and differentiated pricing. With most of our key clients currently taking only one of our six services, the cross-selling opportunity is significant.

We will also pursue disciplined bolt-on M&A in our Core and Accelerate industries to build out leading positions and scale in high-growth markets. Together, these actions give us a clear and structured path to a mid-to-high teens operating EBITDA margin by 2029 and we will assess share buybacks from excess cash following each full-year result. With our capital-light model and strong cash-generation potential, we see a clear pathway to more than double EBITDA over time.”

ARCADIS’ RESET: FOCUSED GROWTH, SUSTAINABLE VALUE

The strategy is built on three value-creation priorities: focus on strengths, simplify around clients and drive a performance culture, underpinned by AI and digital innovation.

FOCUS ON STRENGTHS

Arcadis is actively changing its portfolio, concentrating investment in the sectors and growth markets where its expertise is most recognized by clients and where structural demand is strongest.

  1. Core
    • Where Arcadis holds strong leading positions in structurally growing markets
    • Includes industries Transportation and Energy & Water, 53% of net revenues1)
    • Organic net revenue growth profile of mid to high single digit for Transportation, high single digit for Energy & Water
  2. Accelerate
    • Where Arcadis is scaling rapidly in high-growth sectors, including data centers, life sciences, and semiconductors
    • Includes industries Industrial Manufacturing & Technology, 21% of net revenues
    • Organic net revenue growth profile of mid to high single digit
  3. Optimize
    • Where Arcadis is applying strict margin discipline and divesting non-core assets, including the majority of the Architecture business and China operations
    • Includes Real Estate & Development industry, 26% of net revenues        

Arcadis expects the share of Core and Accelerate industries to grow from 74%1) to 85% of Total Net Revenues by 2029, improving the overall quality and profitability of the business.

Environmental services, a leading business representing approximately 20% of net revenues built over 138 years of industry leadership, will be scaled by embedding across all four industries.

SIMPLIFY AROUND CLIENTS

Arcadis is replacing its Global Business Area structure with a model in which profit and loss accountability follows the client, not the person. Account teams will bring together sales and delivery under one accountable team per account, eliminating duplication, speeding up decision-making and enabling more consistent, end-to-end service. A single global services and delivery business, with real-time visibility of talent and skills across the organisation, replaces the current more fragmented model. Continued growth of Arcadis’ Global Excellence Centers will improve consistency, speed and cost efficiency. AI, automation and standardisation will release capacity for higher-value work.

DRIVE PERFORMANCE CULTURE

Arcadis’ people-first culture is embedded in its ownership model. Building on this principle, Arcadis is building a high-performance culture that is clearer and more focused on impact, through performance-linked incentives, clear ownership of client satisfaction, growth and margins. More than 200 leaders were already appointed in 2026 to create a simpler, flatter and more agile business. The Lovinklaan Foundation, Arcadis’ largest shareholder, reinvests dividends in knowledge exchange, innovation and professional development, giving Arcadians a long-term stake in the company’s success. Combined, this will make Arcadis’ performance culture a direct driver of growth, margin and client impact.

EMBED AI AND DIGITAL

Arcadis is embedding AI and digital directly into how it delivers projects, wins work and operates the business. This is already creating value for clients across sectors, improving productivity, quality and outcomes. Arcadis focuses on structured data, partnerships, in-house capability and disciplined scaling to ensure the best ideas reach clients consistently and globally. Its new partnership with Autodesk is one example of how Arcadis embeds AI directly into the workflows, combining technology with Arcadis’ own data, knowledge and engineering expertise. In addition we see strong AI implementation, resulting from working with Nomic, Arcadis’ AI partner purpose-built for engineering. More than 400 engineers across 17 countries now use over 700 engineer-built workflows to analyze drawings, specifications and process complex project information. Both examples highlight AI in action, creating value.

NON-FINANCIAL TARGETS

The strategy is also underpinned by non-financial commitments. Arcadis has set the following non-financial targets for the 2027-2029 cycle:

  • Client satisfaction score of 85% or above by 2029;
  • Employee Net Promoter Score in the top quartile of the professional services sector;
  • 30% improvement in recordable safety incidents and proactive safety behaviours by 2029;
  • €100 Billion of client project construction value assessed annually through its Future IMPACT+ sustainability framework by 2035.

  1) Based on 2025 full year results 

END

ARCADIS INVESTOR RELATIONS
Christine Disch | +31 (0)615376020 | christine.disch@arcadis.com
Investor calendar: https://www.arcadis.com/en/investors/investor-calendar

CAPITAL MARKETS DAY WEBCAST
Today at 14:00 CET: Capital Markets Day 2026 | General | Arcadis

ABOUT ARCADIS
Arcadis is the world’s leading company delivering data-driven sustainable design, engineering, and consultancy solutions for natural and built assets. We are around 34,000 architects, data analysts, designers, engineers, project planners, water management and sustainability experts, all driven by our passion for improving quality of life. As part of our commitment to accelerating a planet positive future, we work with our clients to make sustainable project choices, combining digital and human innovation, and embracing future-focused skills across the environment, energy and water, buildings, transport, and infrastructure sectors. We operate in over 30 countries and reported €5 billion in gross revenues for 2025. www.arcadis.com

REGULATED INFORMATION
This press release contains information that qualifies or may qualify as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Attachment

Louvain-La-Neuve, Belgium, September 29, 2026 at 7 a.m. CEST – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Istituti Fisioterapici Ospitalieri & Istituto Nazionale Tumori Regina Elena (IFO), to provide a turnkey proton therapy solution in Rome, Italy. The center will be the first gantry-based proton therapy system available in central and southern Italy.

Following a rigorous public tender process, IBA and its partners Cecchini SRL and Gowen SRL, construction companies and RTI (Temporary Grouping of Companies) members, have been selected by IFO to deliver a turnkey compact gantry-based Proteus®ONE1 system at the Istituti Fisioterapici Ospitalieri center in Rome. IFO will use proton therapy treatment modality for both pediatric and adult patients. As proton therapy is not currently available in central or southern Italy, this landmark project will bring the latest and most widely used gantry-based proton therapy technology with proven high clinical versatility to Italian patients. IFO expects to start treating patients in 2030.

The contract includes the supply of the latest-generation proton therapy system, Proteus®ONE, design, build, installation, and a comprehensive training & education program as well as a one-year operation and maintenance agreement. As the market-leading compact proton therapy solution, Proteus®ONE is designed to continuously evolve and integrate the latest technological advancements, enabling IBA users to benefit from cutting-edge innovation and adaptable capabilities.

Henri de Romrée, Deputy Chief Executive Officer of IBA, commented: “We are proud to partner with IFO on this landmark project, which will make gantry-based proton therapy available to patients in central and southern Italy for the first time. With Proteus®ONE, IBA brings a proven, compact gantry solution designed to broaden access to advanced cancer care and support the treatment of a wide range of clinical indications. This collaboration reflects our shared commitment to bringing innovative, high-quality cancer treatments closer to patients.”

Giuseppe Navanteri, Chief Clinical Engineering and Technology officer of IFO, added: “We are pleased to work with IBA to bring proton therapy closer to patients in our region. We are convinced that choosing a gantry-based solution will provide the clinical versatility needed, enabling more patients to benefit from the advantages of proton therapy. This project represents an important step forward in expanding access to advanced cancer care in central and southern Italy.”

The typical end user price of a Proteus®️ONE system with a multiyear maintenance contract ranges between €35 and €45 million.

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.

About IFO

The Istituti Fisioterapici Ospitalieri (IFO) of Rome is one of Italy’s leading public research hospitals and comprises two Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS): the Regina Elena National Cancer Institute (IRE), dedicated to oncology, and the San Gallicano Dermatological Institute (ISG), specialized in dermatology. Founded in 1939, IFO combines patient care, clinical research, education, and innovation, serving as a national and international reference center for cancer treatment, dermatology, translational research, and precision medicine. Located in Rome, IFO is accredited by several international organizations and is recognized for excellence in multidisciplinary patient care, advanced therapies, and scientific research.

CONTACTS
Thomas Pevenage
Investor Relations
+32 10 475 890
investorrelations@iba-group.com

Nathalie van Ypersele
Head of Communication and Sustainability

Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com


1 Proteus®ONE is a brand name of Proteus®235

Attachment

Louvain-La-Neuve, Belgium, September 29, 2026 at 7 a.m. CEST – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a contract with the Istituti Fisioterapici Ospitalieri & Istituto Nazionale Tumori Regina Elena (IFO), to provide a turnkey proton therapy solution in Rome, Italy. The center will be the first gantry-based proton therapy system available in central and southern Italy.

Following a rigorous public tender process, IBA and its partners Cecchini SRL and Gowen SRL, construction companies and RTI (Temporary Grouping of Companies) members, have been selected by IFO to deliver a turnkey compact gantry-based Proteus®ONE1 system at the Istituti Fisioterapici Ospitalieri center in Rome. IFO will use proton therapy treatment modality for both pediatric and adult patients. As proton therapy is not currently available in central or southern Italy, this landmark project will bring the latest and most widely used gantry-based proton therapy technology with proven high clinical versatility to Italian patients. IFO expects to start treating patients in 2030.

The contract includes the supply of the latest-generation proton therapy system, Proteus®ONE, design, build, installation, and a comprehensive training & education program as well as a one-year operation and maintenance agreement. As the market-leading compact proton therapy solution, Proteus®ONE is designed to continuously evolve and integrate the latest technological advancements, enabling IBA users to benefit from cutting-edge innovation and adaptable capabilities.

Henri de Romrée, Deputy Chief Executive Officer of IBA, commented: “We are proud to partner with IFO on this landmark project, which will make gantry-based proton therapy available to patients in central and southern Italy for the first time. With Proteus®ONE, IBA brings a proven, compact gantry solution designed to broaden access to advanced cancer care and support the treatment of a wide range of clinical indications. This collaboration reflects our shared commitment to bringing innovative, high-quality cancer treatments closer to patients.”

Giuseppe Navanteri, Chief Clinical Engineering and Technology officer of IFO, added: “We are pleased to work with IBA to bring proton therapy closer to patients in our region. We are convinced that choosing a gantry-based solution will provide the clinical versatility needed, enabling more patients to benefit from the advantages of proton therapy. This project represents an important step forward in expanding access to advanced cancer care in central and southern Italy.”

The typical end user price of a Proteus®️ONE system with a multiyear maintenance contract ranges between €35 and €45 million.

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals, and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com.

About IFO

The Istituti Fisioterapici Ospitalieri (IFO) of Rome is one of Italy’s leading public research hospitals and comprises two Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS): the Regina Elena National Cancer Institute (IRE), dedicated to oncology, and the San Gallicano Dermatological Institute (ISG), specialized in dermatology. Founded in 1939, IFO combines patient care, clinical research, education, and innovation, serving as a national and international reference center for cancer treatment, dermatology, translational research, and precision medicine. Located in Rome, IFO is accredited by several international organizations and is recognized for excellence in multidisciplinary patient care, advanced therapies, and scientific research.

CONTACTS
Thomas Pevenage
Investor Relations
+32 10 475 890
investorrelations@iba-group.com

Nathalie van Ypersele
Head of Communication and Sustainability

Daniel Ernult
Corporate Communication Manager
+32 10 475 890
communication@iba-group.com


1 Proteus®ONE is a brand name of Proteus®235

Attachment

Press Release

Weekly progress on share repurchase program to cover share plans and reduce capital

Kaiseraugst (Switzerland), Maastricht (Netherlands), September 29, 2026

dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to cover commitments under the Group’s share-based compensation plans and €500 million to reduce its issued capital.

In accordance with regulations, dsm-firmenich informs the market that during the period from September 21, 2026 up to and including September 25, 2026 a total number of 313,835 shares have been repurchased on its behalf. The shares were repurchased at an average price of €96.45 per share for a total amount of €30.3 million. The total number of shares repurchased under this program to date is 6,976,047 shares at an average price of €74.68 for a total consideration of €520.9 million.

The buyback of €40 million worth of shares to cover commitments under the Group’s share-based compensation plans was finalized on March 23, 2026. The €500 million share repurchase program to reduce the Group’s issued capital is intended to be completed by the end of Q3 2026.

For more detailed information see ‘Daily transaction details Share Repurchase Program announced February 9, 2026’.

For more information, please contact:

dsm-firmenich investor relations enquiries:
Email: investors@dsm-firmenich.com

dsm-firmenich media enquiries:
Email: media@dsm-firmenich.com   

About dsm-firmenich
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for people and the planet. dsm-firmenich is a Swiss company, listed on Euronext Amsterdam and SIX Swiss Exchange, with operations in almost 60 countries and revenues of more than €9 billion for its Continuing Operations following the divestment of Animal Nutrition & Health. With a diverse, worldwide team of nearly 21,000 employees, we bring progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com

Disclaimer  

This press release does not constitute or form part of, an offer or any solicitation of an offer for securities in any jurisdiction. This press release may contain forward-looking statements with respect to dsm-firmenich’s future. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions.

Attachment

Press Release

Weekly progress on share repurchase program to cover share plans and reduce capital

Kaiseraugst (Switzerland), Maastricht (Netherlands), September 29, 2026

dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 9, 2026 its intention to repurchase ordinary shares with an aggregate market value of €500 million and reduce its issued capital. On March 12, 2026, the company commenced repurchasing ordinary shares for a total amount of €540 million, of which €40 million to cover commitments under the Group’s share-based compensation plans and €500 million to reduce its issued capital.

In accordance with regulations, dsm-firmenich informs the market that during the period from September 21, 2026 up to and including September 25, 2026 a total number of 313,835 shares have been repurchased on its behalf. The shares were repurchased at an average price of €96.45 per share for a total amount of €30.3 million. The total number of shares repurchased under this program to date is 6,976,047 shares at an average price of €74.68 for a total consideration of €520.9 million.

The buyback of €40 million worth of shares to cover commitments under the Group’s share-based compensation plans was finalized on March 23, 2026. The €500 million share repurchase program to reduce the Group’s issued capital is intended to be completed by the end of Q3 2026.

For more detailed information see ‘Daily transaction details Share Repurchase Program announced February 9, 2026’.

For more information, please contact:

dsm-firmenich investor relations enquiries:
Email: investors@dsm-firmenich.com

dsm-firmenich media enquiries:
Email: media@dsm-firmenich.com   

About dsm-firmenich
As innovators in nutrition, health, and beauty, dsm-firmenich reinvents, manufactures, and combines vital nutrients, flavors, and fragrances for the world’s growing population to thrive. With our comprehensive range of solutions, with natural and renewable ingredients and renowned science and technology capabilities, we work to create what is essential for life, desirable for consumers, and more sustainable for people and the planet. dsm-firmenich is a Swiss company, listed on Euronext Amsterdam and SIX Swiss Exchange, with operations in almost 60 countries and revenues of more than €9 billion for its Continuing Operations following the divestment of Animal Nutrition & Health. With a diverse, worldwide team of nearly 21,000 employees, we bring progress to life every day, everywhere, for billions of people. www.dsm-firmenich.com

Disclaimer  

This press release does not constitute or form part of, an offer or any solicitation of an offer for securities in any jurisdiction. This press release may contain forward-looking statements with respect to dsm-firmenich’s future. Such statements are based on current expectations, estimates and projections of dsm-firmenich and information currently available to the company. dsm-firmenich cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. dsm-firmenich has no obligation to update the statements contained in this press release, unless required by law. This communication contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. The English language version of this press release prevails over other language versions.

Attachment

  • HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing            
  • Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties

Bagsværd, Denmark, 29 September 2026 – Novo Nordisk today announced that it has entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK) for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing.

Under the terms of the agreement, Novo will obtain exclusive rights to develop, manufacture and commercialise HRS-1596 globally, excluding mainland China, Hong Kong, Macao and Taiwan. The potential total value of the agreement is up to 2.6 billion US dollars contingent on the achievement of applicable development, regulatory and commercial milestones. This includes a 300 million dollars upfront payment. In addition, Hengrui Pharma is eligible to receive royalties based on net sales of HRS-1596 within the licensed territory.

“Novo has pioneered the field of oral peptides and as leaders, we continuously look to advance our broad and deep oral pipeline across obesity, diabetes and other cardiometabolic diseases through our strong internal capabilities and leading external innovation,” said Martin Holst Lange, executive vice president, Research & Development and chief scientific officer at Novo. “Hengrui Pharma has a proven track record of discovering and advancing innovative therapies with the patients in the center, and we are excited to add HRS-1596 to our growing pipeline and to explore its potential to raise the bar for convenience in the field.”

“We are committed to continuous innovation, bringing better treatments to patients. HRS-1596 reflects this commitment in metabolic diseases, with the potential to offer the convenience of once-weekly oral administration,” said Frank Jiang, MD, Ph.D., Executive Vice President and Chief Strategy Officer of Hengrui Pharma. “This collaboration brings together Hengrui’s innovation strengths and Novo’s global leadership in GLP-1 therapies and obesity care. Together, we aim to advance this innovative therapy for patients worldwide.”

HRS-1596 is designed to reduce weight and improve glycemic control through multiple mechanisms, including appetite suppression, stimulation of insulin secretion, and improved insulin sensitivity, supporting its potential use in obesity, type 2 diabetes, and other metabolic diseases. HRS-1596 has potential to be developed for once-weekly oral administration, which would substantially reduce dosing frequency and improve convenience compared with current offerings. Hengrui Pharma has received approval in China to initiate phase 1 clinical trials with HRS-1596 for weight management and type 2 diabetes.

The license agreement is subject to clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act and the satisfaction of other customary closing conditions. The transaction is expected to close in the fourth quarter of 2026.

About Hengrui Pharma
Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. For more information, visit us at Hengrui.com and follow us on LinkedIn.

About Novo
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Media:  
Ambre James-Brown
+45 3079 9289
globalmedia@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com
Novo Investors:  
Michael Novod
+45 3075 6050
nvno@novonordisk.com
Sina Meyer
+45 3079 6656
azey@novonordisk.com
Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com
Max Ung
+45 3077 6414
mxun@novonordisk.com
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Mads Berner Bruun
+45 3075 2936
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
Alex Bruce (US)
+1 640 230 0276
axeu@novonordisk.com

Attachment

  • HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing            
  • Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties

Bagsværd, Denmark, 29 September 2026 – Novo Nordisk today announced that it has entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK) for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing.

Under the terms of the agreement, Novo will obtain exclusive rights to develop, manufacture and commercialise HRS-1596 globally, excluding mainland China, Hong Kong, Macao and Taiwan. The potential total value of the agreement is up to 2.6 billion US dollars contingent on the achievement of applicable development, regulatory and commercial milestones. This includes a 300 million dollars upfront payment. In addition, Hengrui Pharma is eligible to receive royalties based on net sales of HRS-1596 within the licensed territory.

“Novo has pioneered the field of oral peptides and as leaders, we continuously look to advance our broad and deep oral pipeline across obesity, diabetes and other cardiometabolic diseases through our strong internal capabilities and leading external innovation,” said Martin Holst Lange, executive vice president, Research & Development and chief scientific officer at Novo. “Hengrui Pharma has a proven track record of discovering and advancing innovative therapies with the patients in the center, and we are excited to add HRS-1596 to our growing pipeline and to explore its potential to raise the bar for convenience in the field.”

“We are committed to continuous innovation, bringing better treatments to patients. HRS-1596 reflects this commitment in metabolic diseases, with the potential to offer the convenience of once-weekly oral administration,” said Frank Jiang, MD, Ph.D., Executive Vice President and Chief Strategy Officer of Hengrui Pharma. “This collaboration brings together Hengrui’s innovation strengths and Novo’s global leadership in GLP-1 therapies and obesity care. Together, we aim to advance this innovative therapy for patients worldwide.”

HRS-1596 is designed to reduce weight and improve glycemic control through multiple mechanisms, including appetite suppression, stimulation of insulin secretion, and improved insulin sensitivity, supporting its potential use in obesity, type 2 diabetes, and other metabolic diseases. HRS-1596 has potential to be developed for once-weekly oral administration, which would substantially reduce dosing frequency and improve convenience compared with current offerings. Hengrui Pharma has received approval in China to initiate phase 1 clinical trials with HRS-1596 for weight management and type 2 diabetes.

The license agreement is subject to clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act and the satisfaction of other customary closing conditions. The transaction is expected to close in the fourth quarter of 2026.

About Hengrui Pharma
Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. For more information, visit us at Hengrui.com and follow us on LinkedIn.

About Novo
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Media:  
Ambre James-Brown
+45 3079 9289
globalmedia@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com
Novo Investors:  
Michael Novod
+45 3075 6050
nvno@novonordisk.com
Sina Meyer
+45 3079 6656
azey@novonordisk.com
Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com
Max Ung
+45 3077 6414
mxun@novonordisk.com
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Mads Berner Bruun
+45 3075 2936
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
Alex Bruce (US)
+1 640 230 0276
axeu@novonordisk.com

Attachment

  • HRS-1596 is a phase 1-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing            
  • Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties

Bagsværd, Denmark, 29 September 2026 – Novo Nordisk today announced that it has entered into a license agreement with Hengrui Pharma (600276.SH; 01276.HK) for HRS-1596, a phase 1-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist, with potential for once-weekly oral dosing.

Under the terms of the agreement, Novo will obtain exclusive rights to develop, manufacture and commercialise HRS-1596 globally, excluding mainland China, Hong Kong, Macao and Taiwan. The potential total value of the agreement is up to 2.6 billion US dollars contingent on the achievement of applicable development, regulatory and commercial milestones. This includes a 300 million dollars upfront payment. In addition, Hengrui Pharma is eligible to receive royalties based on net sales of HRS-1596 within the licensed territory.

“Novo has pioneered the field of oral peptides and as leaders, we continuously look to advance our broad and deep oral pipeline across obesity, diabetes and other cardiometabolic diseases through our strong internal capabilities and leading external innovation,” said Martin Holst Lange, executive vice president, Research & Development and chief scientific officer at Novo. “Hengrui Pharma has a proven track record of discovering and advancing innovative therapies with the patients in the center, and we are excited to add HRS-1596 to our growing pipeline and to explore its potential to raise the bar for convenience in the field.”

“We are committed to continuous innovation, bringing better treatments to patients. HRS-1596 reflects this commitment in metabolic diseases, with the potential to offer the convenience of once-weekly oral administration,” said Frank Jiang, MD, Ph.D., Executive Vice President and Chief Strategy Officer of Hengrui Pharma. “This collaboration brings together Hengrui’s innovation strengths and Novo’s global leadership in GLP-1 therapies and obesity care. Together, we aim to advance this innovative therapy for patients worldwide.”

HRS-1596 is designed to reduce weight and improve glycemic control through multiple mechanisms, including appetite suppression, stimulation of insulin secretion, and improved insulin sensitivity, supporting its potential use in obesity, type 2 diabetes, and other metabolic diseases. HRS-1596 has potential to be developed for once-weekly oral administration, which would substantially reduce dosing frequency and improve convenience compared with current offerings. Hengrui Pharma has received approval in China to initiate phase 1 clinical trials with HRS-1596 for weight management and type 2 diabetes.

The license agreement is subject to clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act and the satisfaction of other customary closing conditions. The transaction is expected to close in the fourth quarter of 2026.

About Hengrui Pharma
Hengrui Pharma is an innovative, global pharmaceutical company dedicated to the research, development and commercialization of high-quality medicines to address unmet clinical needs. Its therapeutic areas of focus include oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Driven by a patient-focused philosophy since its founding in 1970, Hengrui Pharma remains committed to advancing human health by striving to conquer diseases, improve health, and extend lives through the power of science and technology. For more information, visit us at Hengrui.com and follow us on LinkedIn.

About Novo
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. For more information, visit novonordisk.com and follow us on Instagram, LinkedIn, TikTok, Facebook, X and YouTube. 

Contacts for further information

Novo Media:  
Ambre James-Brown
+45 3079 9289
globalmedia@novonordisk.com
Liz Skrbkova (US)
+1 609 917 0632
USMediaRelations@novonordisk.com
Novo Investors:  
Michael Novod
+45 3075 6050
nvno@novonordisk.com
Sina Meyer
+45 3079 6656
azey@novonordisk.com
Christoffer Togo Solgaard-Tullin
+45 3079 1471
cftu@novonordisk.com
Max Ung
+45 3077 6414
mxun@novonordisk.com
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Mads Berner Bruun
+45 3075 2936
mbbz@novonordisk.com
Frederik Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
Alex Bruce (US)
+1 640 230 0276
axeu@novonordisk.com

Attachment

HANOI, Vietnam, Sept. 29, 2026 (GLOBE NEWSWIRE) — EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading Advanced Air Mobility (AAM) technology platform company, today announced that its Global Fast Track Program has expanded to Vietnam: Vietnam has become the second country to join the Program following Sri Lanka, with Hanoi as its first stop, marking EHang’s first city‑level partnership in the country. The Company’s partner, HungViet Technology and Investment Trading JSC (“HungViet”), has signed a Memorandum of Understanding (MOU) with the Hanoi Department of Science and Technology (“Hanoi DOST”) in Hanoi. In accordance with Hanoi’s dedicated procedures for regulatory sandbox testing, the parties will carry out low‑altitude economy sandbox testing of electric vertical take-off and landing (“eVTOL”) aircraft centered on the EH216‑S pilotless human‑carrying aircraft, exploring compliant validation pathways for safe operations. EHang will provide the EH216‑S aircraft and its technological systems in support of the sandbox testing.

Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee; Cu Ngoc Trang, Director of Hanoi Department of Science and Technology, alongside relevant competent officials; Conor Yang, Chief Financial Officer of EHang; Dang Duc Dung, President & CEO of HungViet, and other representatives attended the signing ceremony.
(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee; Cu Ngoc Trang, Director of Hanoi Department of Science and Technology, alongside relevant competent officials; Conor Yang, Chief Financial Officer of EHang; Dang Duc Dung, President & CEO of HungViet, and other representatives attended the signing ceremony.)

Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee delivers remarks at the signing ceremony.
(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee delivers remarks at the signing ceremony.)

Under the MOU, the Hanoi DOST will provide guidance for the application and approval of the sandbox testing, while HungViet, as the local implementing entity, will commit technical, financial and human resources starting from October 2026, prepare the sandbox application materials, and carry out controlled test flights upon receipt of the authorization decision. The EH216‑S pilotless human‑carrying aircraft, operational technology systems and personnel training support involved in the sandbox testing will be provided by EHang. Centered on the sandbox testing, the cooperation will advance in phases at Hoa Lac Hi-Tech Park: conducting controlled test flights of the EH216‑S, building an unmanned aircraft traffic management (UTM) model and an operations control center (OCC) model, while advancing operational technology training, the joint development of technical standards and regulations, and technical exchanges. The sandbox testing will proceed upon completion of the relevant application and approval procedures.

Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee, stated, “Hanoi is in a phase of rapid urban development, and the low‑altitude economy holds tremendous potential. We greatly appreciate EHang’s technical support and collaboration. The signing and execution of this project will strongly advance the development of Hanoi’s low‑altitude economy and science‑innovation industries, drive comprehensive urban development, and ultimately bring benefits to Hanoi residents. Innovative technologies such as pilotless aerial vehicles will also open brand‑new possibilities for Hanoi’s urban mobility and cultural‑tourism growth.”

Under the cooperation plan, the parties will start with regulatory sandbox testing and carry out phased technical verification of the human‑carrying and cargo‑carrying variants of the EH216‑series pilotless eVTOL aircraft in line with Vietnam’s local regulatory rules, real-world operating environments and business implementation conditions, steadily advancing commercial‑operation‑related work. Beyond Hanoi, EHang plans to further expand its business to key Vietnamese cities including Ho Chi Minh City and Da Nang, and to realize diversified commercial‑use scenarios centered around urban commuting and the development of popular tourist destinations.

Anchoring Southeast Asia as a Strategic Hub: EHang Accelerates Implementation of its Global Fast Track Program

On the sidelines of the 61st Conference of Directors General of Civil Aviation, Asia and Pacific Regions (DGCA/61), EHang held discussions with senior representatives of Malaysia’s civil aviation authority, as well as civil aviation directors and delegates from Laos, Fiji, Cambodia, the Philippines, Tonga, Vietnam, Maldives, Bhutan, Nepal and other countries. Participants explored viable paths to deploy regulatory sandbox mechanisms and the Fast Track Program within respective jurisdictions.

Vietnam’s cultural‑tourism market boasts strong growth momentum. According to official Vietnamese statistics, the country received nearly 21.2 million international inbound tourists in 2025, hitting an all‑time high. The booming tourism industry unlocks extensive market space for applications including pilotless eVTOL aerial sightseeing and urban low‑altitude mobility. The signing of the MOU in Hanoi also represents a key advance for EHang’s Global Fast Track Program in Southeast Asia.

Conor Yang, Chief Financial Officer of EHang, commented, “Expanding into overseas markets means far more than exporting aircraft hardware. What matters most is the deep alignment of technology and commercial operations with local regulatory systems. Safety and compliance are the bedrock for the commercial realization of AAM. EHang’s Global Fast Track Program is designed for the regulatory frameworks and market characteristics of individual countries and regions. Through sandbox testing, operational validation and collaboration with local partners, it connects technology, commercial operations and regulation to accelerate commercial roll‑out. Vietnam is a highly innovative and important market within ASEAN. We look forward to working solidly with the Hanoi government on testing and validation activities, accumulating valuable practical experience for the safe and orderly commercial deployment of pilotless eVTOL in the country, and advancing commercial opportunities for low‑altitude mobility across Southeast Asia.”

About EHang
EHang (Nasdaq: EH) is a global‑leading Advanced Air Mobility technology platform company dedicated to making safe, autonomous and eco‑friendly air mobility accessible to everyone. EHang focuses on the research, development and manufacturing of a diversified portfolio of pilotless electric vertical take‑off and landing (eVTOL) aerial vehicles, covering a wide range of application scenarios including aerial tourism, intra‑city commuting, inter‑city travel, logistics transportation and emergency firefighting. EHang’s flagship product, the EH216‑S, has obtained the world’s first type certificate (TC), production certificate (PC) and standard airworthiness certificate (AC) for pilotless passenger‑carrying eVTOL aircraft issued by the Civil Aviation Administration of China (CAAC), and has entered operation under China’s first batch of commercial operation qualifications for pilotless passenger‑carrying eVTOL. In addition, the Company’s long‑range VT35 model further extends inter‑city mobility scenarios, laying the foundation for a multi‑tiered low‑altitude mobility network. Leveraging its advanced autonomous flight technology and scalable operational infrastructure, EHang is redefining the transportation of people and goods — transcending cities, regions and natural barriers to usher in a new era of air mobility. For more information, please visit www.ehang.com.

Safe Harbor Statement
This press release may contain forward‑looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward‑looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “may” and other similar expressions. Statements that are not historical facts, including statements regarding management’s beliefs and expectations, are forward‑looking statements. Forward‑looking statements involve inherent risks and uncertainties. Many factors could cause actual results to differ materially from those contained in any forward‑looking statement, including but not limited to product certification, the Company’s expectations regarding demand for and market acceptance of its products, the commercialization of the Company’s autonomous aerial vehicle products and solutions and Advanced Air Mobility services, its relationships with strategic partners, and the litigation currently involving the Company and potential litigation. The Company’s management has made such forward‑looking statements based on current expectations, assumptions, estimates and projections. While the Company’s management believes that these expectations, assumptions, estimates and projections are reasonable, forward‑looking statements are only predictions of future events and involve known and unknown risks and uncertainties that are difficult for the Company’s management to control. These risks and uncertainties may cause EHang’s actual results of operations, performance or achievements to differ materially from those expressed or implied by any forward‑looking statements.

Media Contact: pr@ehang.com 
Investor Contact: ir@ehang.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/4953a6d8-2bb3-4bc3-a9a5-ec21eb70c8cc

https://www.globenewswire.com/NewsRoom/AttachmentNg/5eff6620-8226-46c4-aa87-4b0ebbb91363

HANOI, Vietnam, Sept. 29, 2026 (GLOBE NEWSWIRE) — EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading Advanced Air Mobility (AAM) technology platform company, today announced that its Global Fast Track Program has expanded to Vietnam: Vietnam has become the second country to join the Program following Sri Lanka, with Hanoi as its first stop, marking EHang’s first city‑level partnership in the country. The Company’s partner, HungViet Technology and Investment Trading JSC (“HungViet”), has signed a Memorandum of Understanding (MOU) with the Hanoi Department of Science and Technology (“Hanoi DOST”) in Hanoi. In accordance with Hanoi’s dedicated procedures for regulatory sandbox testing, the parties will carry out low‑altitude economy sandbox testing of electric vertical take-off and landing (“eVTOL”) aircraft centered on the EH216‑S pilotless human‑carrying aircraft, exploring compliant validation pathways for safe operations. EHang will provide the EH216‑S aircraft and its technological systems in support of the sandbox testing.

Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee; Cu Ngoc Trang, Director of Hanoi Department of Science and Technology, alongside relevant competent officials; Conor Yang, Chief Financial Officer of EHang; Dang Duc Dung, President & CEO of HungViet, and other representatives attended the signing ceremony.
(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee; Cu Ngoc Trang, Director of Hanoi Department of Science and Technology, alongside relevant competent officials; Conor Yang, Chief Financial Officer of EHang; Dang Duc Dung, President & CEO of HungViet, and other representatives attended the signing ceremony.)

Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee delivers remarks at the signing ceremony.
(Photo: Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee delivers remarks at the signing ceremony.)

Under the MOU, the Hanoi DOST will provide guidance for the application and approval of the sandbox testing, while HungViet, as the local implementing entity, will commit technical, financial and human resources starting from October 2026, prepare the sandbox application materials, and carry out controlled test flights upon receipt of the authorization decision. The EH216‑S pilotless human‑carrying aircraft, operational technology systems and personnel training support involved in the sandbox testing will be provided by EHang. Centered on the sandbox testing, the cooperation will advance in phases at Hoa Lac Hi-Tech Park: conducting controlled test flights of the EH216‑S, building an unmanned aircraft traffic management (UTM) model and an operations control center (OCC) model, while advancing operational technology training, the joint development of technical standards and regulations, and technical exchanges. The sandbox testing will proceed upon completion of the relevant application and approval procedures.

Truong Viet Dzung, Vice Chairman of Hanoi People’s Committee, stated, “Hanoi is in a phase of rapid urban development, and the low‑altitude economy holds tremendous potential. We greatly appreciate EHang’s technical support and collaboration. The signing and execution of this project will strongly advance the development of Hanoi’s low‑altitude economy and science‑innovation industries, drive comprehensive urban development, and ultimately bring benefits to Hanoi residents. Innovative technologies such as pilotless aerial vehicles will also open brand‑new possibilities for Hanoi’s urban mobility and cultural‑tourism growth.”

Under the cooperation plan, the parties will start with regulatory sandbox testing and carry out phased technical verification of the human‑carrying and cargo‑carrying variants of the EH216‑series pilotless eVTOL aircraft in line with Vietnam’s local regulatory rules, real-world operating environments and business implementation conditions, steadily advancing commercial‑operation‑related work. Beyond Hanoi, EHang plans to further expand its business to key Vietnamese cities including Ho Chi Minh City and Da Nang, and to realize diversified commercial‑use scenarios centered around urban commuting and the development of popular tourist destinations.

Anchoring Southeast Asia as a Strategic Hub: EHang Accelerates Implementation of its Global Fast Track Program

On the sidelines of the 61st Conference of Directors General of Civil Aviation, Asia and Pacific Regions (DGCA/61), EHang held discussions with senior representatives of Malaysia’s civil aviation authority, as well as civil aviation directors and delegates from Laos, Fiji, Cambodia, the Philippines, Tonga, Vietnam, Maldives, Bhutan, Nepal and other countries. Participants explored viable paths to deploy regulatory sandbox mechanisms and the Fast Track Program within respective jurisdictions.

Vietnam’s cultural‑tourism market boasts strong growth momentum. According to official Vietnamese statistics, the country received nearly 21.2 million international inbound tourists in 2025, hitting an all‑time high. The booming tourism industry unlocks extensive market space for applications including pilotless eVTOL aerial sightseeing and urban low‑altitude mobility. The signing of the MOU in Hanoi also represents a key advance for EHang’s Global Fast Track Program in Southeast Asia.

Conor Yang, Chief Financial Officer of EHang, commented, “Expanding into overseas markets means far more than exporting aircraft hardware. What matters most is the deep alignment of technology and commercial operations with local regulatory systems. Safety and compliance are the bedrock for the commercial realization of AAM. EHang’s Global Fast Track Program is designed for the regulatory frameworks and market characteristics of individual countries and regions. Through sandbox testing, operational validation and collaboration with local partners, it connects technology, commercial operations and regulation to accelerate commercial roll‑out. Vietnam is a highly innovative and important market within ASEAN. We look forward to working solidly with the Hanoi government on testing and validation activities, accumulating valuable practical experience for the safe and orderly commercial deployment of pilotless eVTOL in the country, and advancing commercial opportunities for low‑altitude mobility across Southeast Asia.”

About EHang
EHang (Nasdaq: EH) is a global‑leading Advanced Air Mobility technology platform company dedicated to making safe, autonomous and eco‑friendly air mobility accessible to everyone. EHang focuses on the research, development and manufacturing of a diversified portfolio of pilotless electric vertical take‑off and landing (eVTOL) aerial vehicles, covering a wide range of application scenarios including aerial tourism, intra‑city commuting, inter‑city travel, logistics transportation and emergency firefighting. EHang’s flagship product, the EH216‑S, has obtained the world’s first type certificate (TC), production certificate (PC) and standard airworthiness certificate (AC) for pilotless passenger‑carrying eVTOL aircraft issued by the Civil Aviation Administration of China (CAAC), and has entered operation under China’s first batch of commercial operation qualifications for pilotless passenger‑carrying eVTOL. In addition, the Company’s long‑range VT35 model further extends inter‑city mobility scenarios, laying the foundation for a multi‑tiered low‑altitude mobility network. Leveraging its advanced autonomous flight technology and scalable operational infrastructure, EHang is redefining the transportation of people and goods — transcending cities, regions and natural barriers to usher in a new era of air mobility. For more information, please visit www.ehang.com.

Safe Harbor Statement
This press release may contain forward‑looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward‑looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “may” and other similar expressions. Statements that are not historical facts, including statements regarding management’s beliefs and expectations, are forward‑looking statements. Forward‑looking statements involve inherent risks and uncertainties. Many factors could cause actual results to differ materially from those contained in any forward‑looking statement, including but not limited to product certification, the Company’s expectations regarding demand for and market acceptance of its products, the commercialization of the Company’s autonomous aerial vehicle products and solutions and Advanced Air Mobility services, its relationships with strategic partners, and the litigation currently involving the Company and potential litigation. The Company’s management has made such forward‑looking statements based on current expectations, assumptions, estimates and projections. While the Company’s management believes that these expectations, assumptions, estimates and projections are reasonable, forward‑looking statements are only predictions of future events and involve known and unknown risks and uncertainties that are difficult for the Company’s management to control. These risks and uncertainties may cause EHang’s actual results of operations, performance or achievements to differ materially from those expressed or implied by any forward‑looking statements.

Media Contact: pr@ehang.com 
Investor Contact: ir@ehang.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/4953a6d8-2bb3-4bc3-a9a5-ec21eb70c8cc

https://www.globenewswire.com/NewsRoom/AttachmentNg/5eff6620-8226-46c4-aa87-4b0ebbb91363

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.